Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by Freebirdson Jun 12, 2020 2:02pm
260 Views
Post# 31144351

Corvax still a long ways away...

Corvax still a long ways away...

"Vaxil is advancing its CorVax™ preclinical program to validate effective immune response, including assessing convalescent patient plasma, in vitro cytotoxicity, in vivo immunogenicity and ex vivo T cell proliferation and cytokine release.  We anticipate completing this work in the coming months and if successful, we will prepare for and commence our Phase 1 program once receiving approval to do so.

If we are successful in proving the safety of our COVID-19 Vaccine in Phase 1, we will continue the development of CorVax™ to Phase 2 and 3. Vaxil’s signal peptide platform is more easily and more efficiently scaled up"
 

Hopefully the world has a vaccine sooner than this! IF they ever get "approval" to even begin Phase 1 a few months from now...hoping for a breakthrough like most here but they have a better chance curing cancer IMO ) 

<< Previous
Bullboard Posts
Next >>